A heart attack signal with tiotropium (Spiriva) and a potential genetic explanation for severe adverse events with long-acting beta agonists (LABAs) in asthma topped the news in pulmonology this week.
A heart attack signal with tiotropium (Spiriva) and a potential genetic explanation for severe adverse events with long-acting beta agonists (LABAs) in asthma topped the news in pulmonology this week.